RZB — Reinsurance Group of America, Incorporated

Summary of RZB Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Pretax Adjusted Operating Income: $611 million, or $6.97 per share after tax.
• Adjusted Operating Return on Equity: 16.2% for the trailing twelve months.
• Premium Growth: 5% year-over-year overall; U.S. traditional premium growth at approximately 1%.
• Economic Claims Experience: Favorable by $117 million in Q1, with a cumulative favorable experience of $343 million since 2023.
• Share Repurchases: $50 million in Q1, totaling $175 million since reinstating buybacks.
• Excess Capital: Estimated at $2.4 billion, with deployable capital of $2.9 billion.

2. Strategic Updates and Business Highlights

• Strong performance across all regions, particularly in Asia Pacific and EMEA, driven by new business and favorable claims experience.
• Successful execution of strategic underwriting initiatives in the U.S., contributing to robust individual life activity.
• Continued focus on disciplined capital deployment, with $338 million allocated to in-force transactions in Q1.
• Emphasis on leveraging competitive advantages, including biometric expertise and a diversified global platform.
• Ongoing momentum in longevity transactions and strong client relationships, particularly in EMEA and Asia.

3. Forward Guidance and Outlook

• Confidence in achieving intermediate-term financial targets and long-term shareholder value.
• Anticipation of continued strong fundamentals and a healthy pipeline for 2026 and beyond.
• Expected variable investment income return of 7% for 2026, below long-term expectations of 10-12% due to muted real estate sales.

4. Bad News, Challenges, or Points of Concern

• Declining traditional premium growth in the U.S. attributed to strategic recaptures of lower-quality treaties.
• Potential competitive pressures from European multiline reinsurers as the P&C cycle softens.
• Increased scrutiny on regulatory capital calculations, with a $200 million negative adjustment impacting excess capital estimates.
• The impact of the Equitable and Corebridge merger on existing flow reinsurance agreements remains uncertain.

5. Notable Q&A Insights

• Management expressed confidence in capital deployment strategies, indicating a focus on quality over quantity in transactions.
• The favorable mortality trends in the U.S. were attributed to lower claim frequencies; however, the long-term impact of GLP-1 medications on mortality assumptions remains to be fully assessed.
• The company does not foresee significant impacts from new U.K. regulations related to captive reinsurance, as most of their longevity business operates on a swap basis.
• Future earnings recognition of the $343 million favorable economic claims experience is expected to be gradual, approximately $20 million annually.

Overall, RZB demonstrated a strong start to 2026 with solid financial performance and strategic execution, while also navigating challenges related to competition and regulatory adjustments.